Elixira
Tess Fries is the inventor and founder of Elixira, a patent-pending nanobot platform designed 2025 for lifelong, autonomous cancer prevention. She is also the founder of Nanoism, a medical discipline in preventive medicine that focuses on autonomous, lifelong prevention through the integration of nanotechnology, artificial intelligence, and self-powered nanoscale systems.
Key publications:
Fries, T. (2025). Elixira: A Feasibility Framework for AI-Guided Nanomedicine in Cancer Prevention. [White paper] Zenodo. https://doi.org/10.5281/zenodo.16970549
Fries, T. (2025). Nanoism: The Emergence of a New Medical Field in Preventive Medicine. [White paper] Zenodo. https://doi.org/10.5281/zenodo.16990051
Fries, T. (2025). Elixira: A Multidisease Prevention Platform – Evolving the Future of Lifelong Preventive Medicine. [White paper] Zenodo. https://doi.org/10.5281/zenodo.17014474
With a focus on bridging nanotechnology, biotechnology, and AI, Tess is dedicated to creating transformative healthcare solutions that transcend preventive medicine. Her vision is to accelerate the transition towards a world where advanced technology and ethics work hand in hand to eliminate disease and extend human health.
This person is not in any teams
This person is not in any offices
Elixira
1 followers
Invented and founded by Tess Fries, Elixira is a next-generation, patent-pending, AI-guided nanobot platform designed as a one-time injection for lifelong, autonomous prevention across all cancer types. Its technical feasibility has been independently confirmed by a leading Contract Research Organization (CRO), and all core technologies underlyingElixira have been peer-reviewed and validated. A detailed technical feasibility report is available to prospective partners under NDA. Developed on in vivo–proven nanotechnology and biomedical engineering principles, Elixira integrates self-sustaining energy systems and multiple elimination methods to enable a proactive, continuous prevention model. Operating autonomously inside the human body, it detects, targets, and neutralizes cancer cells in real time — powered entirely by its own renewable energy systems. Engineered for global scalability, ethical accessibility, and minimal infrastructure requirements, Elixira’s mission is to advance preventive cancer care worldwide — enabling earlier detection, intervention, and improved long-term health outcomes.